Porsolt SAS, a preclinical in vivo efficacy and safety CRO, has acquired Fluofarm, expanding its capabilities and services that can assist clients at earlier stages of their drug discovery programs.

“The acquisition of Fluofarma complements Porsolt’s extensive drug discovery portfolio of services and capabilities addressing multiple stages of the drug discovery process,” said Guillaume Froget, president and chief executive officer, Porsolt. “This is an exciting development for Porsolt as we continue to grow to meet the needs of our well established global client base.”

Porsolt is a long established preclinical CRO with an international reputation for expertise in physio-pathological models, customized procedures, and tailored solutions for discovering treatments in multiple disease areas, including psychiatric and neurological disorders, acute and chronic pain, inflammation, cardiac and vascular diseases, metabolic and eating disorders, and dermatology, using disease models in multiple species. Porsolt also provides GLP safety evaluation of drug candidates from screening to regulatory studies before first-in-man administration, including full assessment of arrhythmogenic risk and abuse and dependence liability.